PALADIN Consortium

A novel consortium working to become a central place for PAGs and Industry to collaborate to transform the pace of medicine’s development. ~ In recent years, through forums like FDA Patient-Focused Drug Development meetings and social media, patient communities and their families are calling upon their advocacy organizations, health care providers, drug developers and the clinical research enterprise to communicate and collaborate more effectively in order to accelerate the development of new therapies, with the ultimate goal of increasing access to life-saving treatments. The launch of PALADIN is an exciting and important step to establish more effective relationships between patient advocacy groups and industry. We look forward to working together to develop consensus-based guidelines, training, resources and competencies that will optimize patient advocacy group- biopharmaceutical company collaborations. Ultimately, we believe PALADIN’s impact will enable more consistent, effective and efficient engagements that accelerate the development of new medical therapies and better align medicines development with patient needs. It is our hope that PALADIN will continue to innovate and support advocacy-industry collaborations well beyond its launch year. While the focus for year 1 is on the US ecosystem, the Consortia members believe there will be a future opportunity to leverage learnings to other countries and adjust for local regulations and laws.